Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


My previous session
Most popular
Real-time Quote. Real-time Tradegate - 03/26 07:15:50 am
78.345 EUR   +0.49%
03/25Lexicon Pharma Shares Down Almost 10% on FDA Rejection
03/25GLOBAL MARKETS LIVE : Apple, Apax, Boeing, Daimler…
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi: Availability of the Pre-quarterly Results Communication

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2019 | 05:31pm EDT

Availability of the Pre-quarterly Results Communication

Paris, France - January 11, 2019 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's website:

As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fourth-quarter 2018 results will be published on February 7, 2019.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contact
Jack Cox
Tel.: +33 (0)1 53 77 46 46

Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04:58aSANOFI : and Lexicon`s Zynquista denied type 1 diabetes approval by FDA complete..
03/25Lexicon Pharma Shares Down Almost 10% on FDA Rejection
03/25GLOBAL MARKETS LIVE : Apple, Apax, Boeing, Daimler…
03/23LEXICON PHARMACEUTICALS : to Host Conference Call and Webcast Today, March 22, 2..
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
03/22FDA Rejects Oral Treatment for Type 1 Diabetes
03/22SANOFI : FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
03/22SANOFI : Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 C..
03/22UNIVERSITY OF DUNDEE : Exscientia announces new AI pharma collaboration
03/22ROCHE : Celgene and Evotec's partner Exscientia enter 3-year AI drug discovery c..
More news
Financials (€)
Sales 2019 36 172 M
EBIT 2019 9 222 M
Net income 2019 5 147 M
Debt 2019 14 002 M
Yield 2019 4,08%
P/E ratio 2019 17,87
P/E ratio 2020 15,97
EV / Sales 2019 3,08x
EV / Sales 2020 2,86x
Capitalization 97 296 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 83,4 €
Spread / Average Target 7,0%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI3.04%110 044
JOHNSON & JOHNSON5.86%363 761
NOVARTIS10.09%237 528
ROCHE HOLDING LTD.10.42%232 888
PFIZER-4.03%232 565